- So Now You Can’t Give Microsoft Away?
- Groupon Needs More Disclosure: Analyst
- China’s Steelmakers Set for Turnaround: Analyst
- Bulls Bet Silicon Motion Will Bounce
- Tobacco Stocks a Hot Dividend Play: Analyst
- Forget the Earnings, Disney’s Issue Is the Multiple: Analyst
- Drug Stocks Do Well in ‘Gloom and Doom’ Market: Analyst
- 6 Stocks Unworthy of Biotech Bull Market
ABOUT THE CNBC STOCK BLOG
RSS FEED
CNBC EXPLAINS
CNBC Stock Blog
Text Size 
New Times Are Boosting New Stocks
This is not your garden-variety recession, and Ken Kam of Marketocracy Masters 100 says it means the market of the future will be a lot different from the market of the past.
"The market has fundamentally changed," he told CNBC. "A lot of people who are holding onto stocks, hoping that when things get back to normal that their stocks will get back to even, I think are going to be surprised."
He sees new sectors leading the market when it does come back. So what sectors is he talking about, and whose stocks does he like in those sectors?
Recommendations:
Start with health care, and DepoMed [DEPO
Loading...
()
], a name not often mentioned.
"DepoMed is a small-cap biotech stock," he said. "Biotech and pharmaceuticals are bright spots, because pharmaceuticals have very strong cash flow, so of all industries they have the least need for bank financing."
Kam concedes the sector, too, must change, as patented products go generic, and he sees DepoMed as a prime candidate for acquisition, in a consolidation wave that just saw Pfizer [PFE
Loading...
()
] acquire Wyeth [WYE
Loading...
()
].
"I woult put Cephalon [CEPH
Loading...
()
] in the same category," he added.
He also likes Novo Nordisk [NOVO
Loading...
()
].
Disclosures:
Disclosure information for Ken Kam was not immediately available.
Data is a real-time snapshot *Data is delayed at least 15 minutes
